Kyowa Kirin moo-ves out of transgenic cows as it offloads Hematech
This article was originally published in Scrip
Some seven and a half years after the US firm was acquired to bolster Kirin Brewery's antibody production capabilities, Kyowa Hakko Kirin has divested its Hematech subsidiary to a US healthcare group.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.